Diphenhydramine

Evidence Level: L5

Predicted Indications: 1

Diphenhydramine

Pharmacist Assessment Report

Diphenhydramine: First-generation H1 histamine receptor antagonist → rosacea conjunctivitis

One-Sentence Summary

Diphenhydramine is a first-generation H1 antihistamine, marketed in India in oral capsule, tablet and syrup forms. The TxGNN model predicts it may be effective for rosacea conjunctivitis, but no clinical trials and no publications were found to support this direction, so the prediction rests on the model alone.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	rosacea conjunctivitis
TxGNN Prediction Score	0.9920
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Based on well-established pharmacology, diphenhydramine blocks H1 histamine receptors and also has mild anticholinergic and local anesthetic effects. In theory this could ease ocular itching and redness.

The link to rosacea conjunctivitis is weak. Rosacea-related eye disease is driven mainly by meibomian gland dysfunction, an unstable tear film, Demodex and bacterial colonization, and neurovascular and innate-immune dysregulation (for example MMPs, IL-1 and TNF). Histamine plays a minor or unproven role in these processes.

The high score (0.9920) most likely reflects the drug’s similarity to other conjunctivitis-related uses rather than disease-specific mechanistic evidence. It should be read as a model-ranking signal, not as proof of benefit.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

India Market Information

At least 20 valid single-ingredient licences are recorded, and the list may be partial. Up to 5 are shown below. None carries approved-indication text in the local data.

Authorization Number	Product Name	Dosage Form	Approved Indication
28971	Benacof 25mg Soft Gelatin Capsule	Strip of 10 soft gelatin capsules	Not recorded
145847	Matdryl Syrup	Bottle of 100 ml syrup	Not recorded
21615	Aden-Rex Syrup	Bottle of 100 ml syrup	Not recorded
154621	Novadryl 25mg Capsule	Strip of 10 capsules	Not recorded
115754	Kuffdryl 25mg Tablet	Strip of 10 tablets	Not recorded

Safety Considerations

Drug Interactions: The interaction database lists 394 interacting drugs. Examples of the two Major interactions:

Potassium citrate
Eliglustat

Many Moderate interactions are also listed, mostly with other anticholinergic or central nervous system–acting drugs, including hyoscyamine, atropine, glycopyrronium, dicyclomine, loperamide, morphine, bupropion, metoclopramide and dronabinol.

Please refer to the package insert for warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction is supported only by the model score. No trial or publication addresses rosacea conjunctivitis, and its main disease mechanisms are only loosely related to histamine blockade. Evidence level is L5.

To proceed, the following is needed:

Literature and trial searches specific to rosacea-associated ocular disease and antihistamine use
Preclinical or mechanistic data on histamine’s role in rosacea conjunctivitis
Assessment of whether an ocular formulation or route is feasible, since the marketed forms are oral
Package insert warnings and contraindications, plus a safety review for the ocular setting and for people taking interacting drugs
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.